The purpose of this paper was to determine the effects of hemolysis and patient surgery on levels of microRNA (miRNA, miR) differentially expressed in plasma from colorectal cancer (CRC) patients and healthy controls.
Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer.
Zanutto S, Pizzamiglio S, Ghilotti M, Bertan C, Ravagnani F, Perrone F, Leo E, Pilotti S, Verderio P, Gariboldi M, Pierotti MA
Purpose
Conclusion
Regardless of the inclusion of hemolyzed specimens, miR-378 levels were able to discriminate between the plasma from healthy individuals and those with CRC and between plasma obtained pre-surgery and 4-6 months post-surgery. Conversely, the ability of to discriminate plasma from healthy and CDC patients using miR-21 was influenced by inclusion of hemolysed specimens.
Studies (1)
Purpose
The purpose of this study was to determine the effects of including hemolyzed specimens when comparing plasma miRNA levels between CRC patients and healthy controls or CRC patients pre- and post-surgical excision. EDTA plasma was obtained from 65 CRC patients (stages I-IV) the day before surgery, from 46 CRC patients 4-6 months post-surgery and from 70 healthy blood donors. All plasma specimens were stored at -80˚C until analysis. RNA was extracted using a modified Trizol or QIazol reagent protocol which included the miRNeasy Mini Kit columns. miRNA were quantified using Taqman assays. Specimens were considered hemolyzed if the ratio of the absorbance at 414 nm and 375 nm was ≤2.
Summary of Findings
Plasma levels of miR-21 and miR-378 were higher in CRC patients than in healthy individuals (p=0.046 and p=0.001, respectively), but when analysis was restricted to hemolysis-free plasma, only the difference in miR-378 was significant (p=0.023). Further, plasma levels of miR-378 were lower 4-6 months following CRC surgery than pre-surgical levels, regardless of whether all specimens or only hemolysis-free plasma were included (p<0.0001 and p=0.0002, respectively). miR-21 levels were not significantly affected by surgery.
Biospecimens
FluidPlasmaPreservation Types
FrozenDiagnoses
NeoplasticCarcinomaNormalPlatforms
RNAReal-time qRT-PCRCell count/volumeSpectrophotometryPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition CRCHealthyBiospecimen Acquisition Time of biospecimen collection 1 day before surgery4-6 months post-surgeryBiospecimen Aliquots and Components Hemolysis AbsentPresentReal-time qRT-PCR Specific Targeted nucleic acid miR-21miR-378